“Growing Emphasis on Immunization and Zoonotic Disease Control”
- A significant and accelerating trend in the Middle East and Africa animal and human vaccines market is the rising emphasis on immunization programs for both humans and animals to combat the increasing burden of infectious and zoonotic diseases
- For instance, in January 2024, the World Health Organization (WHO) collaborated with the Ministries of Health across several African nations to expand measles and polio vaccination coverage through mobile outreach programs. These efforts are enhancing vaccine access in rural and underserved areas, fueling market growth for human vaccines in the region
- On the animal health front, government-backed campaigns aimed at eradicating rabies, foot-and-mouth disease, and brucellosis are increasing the demand for veterinary vaccines. In April 2023, Boehringer Ingelheim announced a renewed partnership with African veterinary authorities to supply livestock vaccines, addressing a major cause of economic loss in agriculture-dependent communities
- Moreover, international aid programs and non-governmental organizations (NGOs) such as GAVI and UNICEF are supporting the procurement and distribution of routine childhood vaccines, strengthening the infrastructure and funding for the human vaccine sector in the Middle East and Africa
- The ongoing emergence of zoonotic diseases such as Rift Valley fever and Middle East Respiratory Syndrome (MERS) has further spotlighted the “One Health” approach—encouraging integrated vaccination efforts for both human and animal populations to prevent cross-species outbreaks
- The market is also seeing expansion through technological innovations like thermostable vaccines and combination vaccines, which simplify distribution and increase uptake, particularly in remote areas with limited cold chain access
- As awareness rises about the economic and health impacts of preventable diseases, the demand for cost-effective and accessible vaccine solutions continues to grow, positioning the Middle East and Africa as a high-potential region for both global and local vaccine manufacturers
